Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. (Q51986876)

19 April 2018

title

Disease management of atopic dermatitis: an updated practice parameter. Joint Task Force on Practice Parameters. (English)

1 reference

19 April 2018

1 reference

1 reference

11

Jay M Portnoy

1 reference

19 April 2018

author name string

Donald Y M Leung

1

1 reference

19 April 2018

Richard A Nicklas

2

1 reference

19 April 2018

James T Li

3

1 reference

19 April 2018

I Leonard Bernstein

4

1 reference

19 April 2018

Joann Blessing-Moore

5

1 reference

19 April 2018

Mark Boguniewicz

6

1 reference

19 April 2018

Jean A Chapman

7

1 reference

19 April 2018

David A Khan

8

1 reference

19 April 2018

David Lang

9

1 reference

19 April 2018

Rufus E Lee

10

1 reference

19 April 2018

Diane E Schuller

12

1 reference

19 April 2018

Sheldon L Spector

13

1 reference

19 April 2018

Stephen A Tilles

14

1 reference

19 April 2018

publication date

1 September 2004

1 reference

19 April 2018

Annals of Allergy, Asthma & Immunology

published in

1 reference

19 April 2018

volume

93

1 reference

19 April 2018

issue

3 Suppl 2

1 reference

19 April 2018

page(s)

S1-21

1 reference

19 April 2018

Allergen sensitization through the skin induces systemic allergic responses

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Systematic review of treatments for atopic eczema.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Comparison of results of skin tests, RAST, and double-blind, placebo-controlled food challenges in children with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Presence of IgE antibodies to staphylococcal exotoxins on the skin of patients with atopic dermatitis. Evidence for a new group of allergens

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Evaluation of the staphylococcal exotoxins and their specific IgE in childhood atopic dermatitis☆☆☆

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Effects of cefuroxime axetil on Staphylococcus aureus colonization and superantigen production in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Atopic dermatitis: new insights and opportunities for therapeutic intervention

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Antigen-presenting cells in allergy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Randomised controlled trial of advice on an egg exclusion diet in young children with atopic eczema and sensitivity to eggs

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Improvement in atopic dermatitis in infants with the introduction of an elemental formula

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Topical steroids under wet-wrap dressings in atopic dermatitis--a vehicle-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Treatment of refractory atopic dermatitis using 'wet-wrap' dressings and diluted corticosteroids: results of standardized treatment in both children and adults

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Recombinant interferon gamma therapy for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Successful long-term treatment of severe atopic dermatitis with mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Clinical improvement and significant reduction of total serum IgE in patients suffering from severe atopic dermatitis treated with oral azathioprine

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Worldwide variations in the prevalence of symptoms of atopic eczema in the International Study of Asthma and Allergies in Childhood.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Disease management of atopic dermatitis: a practice parameter. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Counci

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

The role of lymphocytes in allergic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Expression of IL-18 mRNA and secretion of IL-18 are reduced in monocytes from patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Clinical and immunologic variables in skin of patients with atopic eczema and either positive or negative atopy patch test reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Lipid abnormalities in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

High-expression of sphingomyelin deacylase is an important determinant of ceramide deficiency leading to barrier disruption in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Factors associated with the development of peanut allergy in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Six-month controlled study of effect of desoximetasone and betamethasone 17-valerate on the pituitary-adrenal axis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Fluticasone propionate 0.05% cream once daily versus clobetasone butyrate 0.05% cream twice daily in children with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Frequency of application of topical corticosteroids: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. The Netherlands Adult Atopic DermatitisStudy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Tacrolimus (FK506): new treatment approach in superantigen-associated diseases like atopic dermatitis?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Long-term efficacy of tacrolimus ointment for recalcitrant facial erythema resistant to topical corticosteroids in adult patients with atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Eczema herpeticum during treatment of atopic dermatitis with 0.1% tacrolimus ointment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Pimecrolimus (Elidel, SDZ ASM 981)--preclinical pharmacologic profile and skin selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Prevention of acute urticaria in young children with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Therapeutic effect of loratadine on pruritus in patients with atopic dermatitis. A multi-crossover-designed study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Self-potentiating allergic contact dermatitis caused by doxepin hydrochloride cream

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. The Doxepin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Abnormal skin irritancy in atopic dermatitis and in atopy without dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Food allergy. Part 1: immunopathogenesis and clinical disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Quantitative IgE antibody assays in allergic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Utility of food-specific IgE concentrations in predicting symptomatic food allergy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Improved screening for peanut allergy by the combined use of skin prick tests and specific IgE assays

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Dose-response in double-blind, placebo-controlled oral food challenges in children with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Predictors of positive food challenge outcome in non-IgE-mediated reactions to food in children with atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Induction of atopic dermatitis by inhalation of house dust mite

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Exposure to a high concentration of mite allergen in early infancy is a risk factor for developing atopic dermatitis: a 3-year follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Effect of house dust mite avoidance measures in children with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Effect of house dust mite avoidance measures in children with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Double-blind controlled trial of effect of housedust-mite allergen avoidance on atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Effectiveness of occlusive bedding in the treatment of atopic dermatitis - a placebo-controlled trial of 12 months' duration

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

The biology of dust mites and the remediation of mite allergens in allergic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Topical corticosteroids and Staphylococcus aureus in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Preferential binding of Staphylococcus aureus to skin sites of Th2-mediated inflammation in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Fibronectin and fibrinogen contribute to the enhanced binding of Staphylococcus aureus to atopic skin

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Endogenous antimicrobial peptides and skin infections in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Perforin hyperreleasability and depletion in cytotoxic T cells from patients with exacerbated atopic dermatitis and asymptomatic rhinoconjunctivitis allergica

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Eczema herpeticum. Clinical and laboratory features

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Increasing incidence of eczema herpeticum: analysis of seventy-five cases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Smallpox vaccination: Risk considerations for patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Serum IgE reactivity to Malassezia furfur extract and recombinant M. furfur allergens in patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Systemic ketoconazole is an effective treatment of atopic dermatitis with IgE-mediated hypersensitivity to yeasts

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Different expression of cytokine and membrane molecules by circulating lymphocytes on acute mental stress in patients with atopic dermatitis in comparison with healthy controls.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Levels of circulating CD8(+) T lymphocytes, natural killer cells, and eosinophils increase upon acute psychosocial stress in patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Effect of stress on atopic dermatitis: investigation in patients after the great hanshin earthquake

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Behavioural treatment of scratching in patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Biofeedback treatment of atopic dermatitis: controlled case studies of eight cases

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

The effectiveness of wet wrap dressings using 0.1% mometasone furoate and 0.005% fluticasone proprionate ointments in the treatment of moderate to severe atopic dermatitis in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Specific hyposensitization in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

High-dose UVA1 therapy in the treatment of patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Long-term efficacy of medium-dose UVA1 phototherapy in atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Cyclosporin for atopic dermatitis in children.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Interferon-gamma therapy reduces blood leukocyte levels in patients with atopic dermatitis: correlation with clinical improvement

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Long-term therapy with recombinant interferon-gamma (rIFN-gamma) for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Azathioprine for atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Traditional Chinese medicine for the treatment of dermatologic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Traditional Chinese medicine for eczema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Chemical mediators in atopic dermatitis: involvement of leukotriene B4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Increased urinary leukotriene E4 excretion in patients with atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961385-3

7 January 2021

10.1016/S1081-1206(10)61385-3

Identifiers

DOI

1 reference

19 April 2018

1 reference

19 April 2018